Broader industry adoption of voluntary caps on annual price increases for brands could go a long way toward taking the heat off manufacturers on drug pricing, Express Scripts Holding Co.Chief Medical Officer Steve Miller suggested during a panel discussion during the FDA/CMS Summit Dec. 14.
In an exchange with co-panelist Ron Cohen, CEO of Acorda Therapeutics Inc., Miller indicated that restraint on annual price...






